Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 20

    1.

    Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.

    Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL, O'Connell MB, Ohar JA, Young TR; Enoxaparin Clinical Trial Group.

    J Bone Joint Surg Am. 2001 Jun;83-A(6):900-6.PMID: 11407799 [PubMed - indexed for MEDLINE]Related articles

    2.

    Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.

    Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, Landon GC, Jové M; Enoxaparin Clinical Trial Group.

    J Bone Joint Surg Am. 2001 Mar;83-A(3):336-45.PMID: 11263636 [PubMed - indexed for MEDLINE]Related articles

    3.

    Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

    Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

    Ann Intern Med. 2001 Feb 6;134(3):191-202.PMID: 11177331 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin.

    de Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorensen SV.

    Arch Intern Med. 2000 Nov 13;160(20):3160-5.PMID: 11074747 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.
    6.

    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.

    Colwell CW Jr, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA Jr, Ritter MA.

    Clin Orthop Relat Res. 1995 Dec;(321):19-27.PMID: 7497668 [PubMed - indexed for MEDLINE]Related articles

    7.

    Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.

    Colwell CW Jr, Spiro TE.

    Clin Orthop Relat Res. 1995 Oct;(319):215-22.PMID: 7554633 [PubMed - indexed for MEDLINE]Related articles

    8.

    Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.

    Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, et al.

    Circulation. 1994 Aug;90(2):908-14.PMID: 8044962 [PubMed - indexed for MEDLINE]Related articles

    9.

    Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group.

    Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasier RB, Tremaine MD.

    Ann Intern Med. 1994 Jul 15;121(2):81-9.PMID: 8017740 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty. A pilot study.

    Trowbridge A, Boese CK, Woodruff B, Brindley HH Sr, Lowry WE, Spiro TE.

    Clin Orthop Relat Res. 1994 Feb;(299):203-8.PMID: 8119019 [PubMed - indexed for MEDLINE]Related articles

    11.

    Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.

    Colwell CW Jr, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, Comerota AJ, Skoutakis VA.

    J Bone Joint Surg Am. 1994 Jan;76(1):3-14. Erratum in: J Bone Joint Surg Am 1994 Mar;76(3):4741. PMID: 8288662 [PubMed - indexed for MEDLINE]Related articles

    12.

    Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications.

    Carter CA, Skoutakis VA, Spiro TE, West ME, Tooms RE, Joe RH, Knutson TJ.

    Ann Pharmacother. 1993 Oct;27(10):1223-30. Review.PMID: 8251693 [PubMed - indexed for MEDLINE]Related articles

    13.

    Laboratory tests during clinical trials (Document E, Stage 3, Version 1).

    Guelfi JF, Delwaide P, Migne J, Spiro TE, Tognoni G, Breuer J, Tryding N, Malya PA.

    Ann Biol Clin (Paris). 1988;46(9):764-9. English, French. No abstract available. PMID: 3223637 [PubMed - indexed for MEDLINE]Related articles

    14.

    International Federation of Clinical Chemistry (IFCC) Scientific Committee: drug interferences and drug effects in clinical chemistry. Part 5. Laboratory tests during clinical trials.

    Spiro TE, Malya PA, Breuer J, Delwaide P, Tryding N, Tognoni G, Galteau MM, Salway J, Siest G.

    J Clin Chem Clin Biochem. 1987 Mar;25(3):185-9. No abstract available. PMID: 3598472 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pharmacokinetics of intravenous clindamycin in newborn infants.

    Koren G, Zarfin Y, Maresky D, Spiro TE, MacLeod SM.

    Pediatr Pharmacol (New York). 1986;5(4):287-92.PMID: 3737273 [PubMed - indexed for MEDLINE]Related articles

    16.

    Oral neomycin sulfate and erythromycin base before colon surgery: a comparison of serum and tissue concentrations.

    DiPiro JT, Patrias JM, Townsend RJ, Bowden TA Jr, Hooks VH 3rd, Smith RB, Spiro TE.

    Pharmacotherapy. 1985 Mar-Apr;5(2):91-4.PMID: 4000983 [PubMed - indexed for MEDLINE]Related articles

    17.

    Minoxidil in breast milk.

    Valdivieso A, Valdés G, Spiro TE, Westerman RL.

    Ann Intern Med. 1985 Jan;102(1):135. No abstract available. PMID: 3966734 [PubMed - indexed for MEDLINE]Related articles

    18.

    Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents.

    Spiro TE, Mattelaer MA, Efira A, Stryckmans P.

    J Natl Cancer Inst. 1981 Jun;66(6):1053-9.PMID: 6941040 [PubMed - indexed for MEDLINE]Related articles

    19.

    Chemotherapeutic sensitivity of normal and leukemic hematopoietic progenitor cells to N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulfonamide, a new anticancer agent.

    Spiro TE, Socquet M, Delforge A, Stryckmans P.

    J Natl Cancer Inst. 1981 Apr;66(4):615-8.PMID: 6939909 [PubMed - indexed for MEDLINE]Related articles

    20.

    A study of street heroin lots for the presence of the hepatitis B surface antigen.

    Spiro TE, Jaffe R, Holland PV, Alter HJ.

    Drug Alcohol Depend. 1978 Nov;3(6):393-7.PMID: 720209 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Search details

    » See more...